REGULATORY
Shock, Anaphylaxis Added to Xofluza’s ADR List; Label Changes for Checkpoint Blockers
The Ministry of Health, Labor and Welfare (MHLW) on June 4 ordered label revisions related to adverse reactions for a batch of drugs including Shionogi’s novel flu drug Xofluza (baloxavir marboxil) and immune checkpoint inhibitors. Xofluza will add shock and…
To read the full story
REGULATORY
- DMD Gene Therapy Elevidys Cleared for NHI Listing at 305 Million Yen
February 13, 2026
- MHLW Orders Label Revisions for Vyxeos, Inlyta, Imbruvica, and More Drugs
February 13, 2026
- MHLW Orders Label Revisions for Sulfite-Containing Medical Products
February 13, 2026
- PMDA Urges Proper Use of Colchicine, Advises against High-Dose Administration
February 12, 2026
- PMDA to Offer Priority Consultations for Overseas Startups
February 12, 2026
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…





